Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
VANCOUVER, BC – April 9, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing
April 9, 2024
